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Introduction
Psychotic disorders such as schizophrenia have a lifetime prevalence of more than 1% and are a major cause of disease burden in young adults (1) . Antipsychotic medications (dopamine D 2/3 receptor antagonists) are the mainstay of treatment for acute psychosis, and reduce risk of relapse in the longer term (2) . Antipsychotics, however, have limited efficacy in a substantial proportion of patients, from illness onset (3) (4) (5) . The use of antipsychotics is also limited by poor tolerability (6) .
Thus, there is a need to understand the neurobiology underlying treatment response, to guide development of alternative treatments (7) .
The dopamine hypothesis is one of the leading neurobiological hypotheses of psychosis (8) (9) (10) (11) . A meta-analysis of imaging studies found the predominant dopamine abnormalities seen in schizophrenia involve the pre-synaptic dopamine system, including elevated striatal dopamine synthesis capacity (indexed as influx rate constant, Ki cer ), using 18 
F-DOPA Positron Emission
Tomography (PET) (12) . Moreover, striatal dopamine synthesis capacity increases longitudinally with onset of psychosis (13) , and striatal dopamine release is greater in patients who are acutely unwell relative to stable patients (14) . Added to cross sectional studies in which dopamine synthesis capacity has been related to psychotic symptoms (15, 16) , this suggests dopamine function to have a "state" component in psychosis.
Consistent with these findings and the dopamine hypothesis, antipsychotic drugs are all dopamine D 2/3 receptor blockers (17) (18) (19) . Antipsychotic drugs may also act pre-synaptically, to reduce dopamine neuron firing, and this could be their primary mode of therapeutic action (20) . Support for this comes from rodent studies, which have shown sub-chronic treatment with haloperidol and a number of other first as well as second generation antipsychotics induces depolarization blockade of dopamine neurons (20, 21) . Prolonged treatment leads to decreased firing of dopamine neurons in A9 (substantia nigra) and A10 (ventral tegmental area) (22) . The effects of antipsychotics on dopamine neuron firing have also been tested in a neurodevelopmental animal model of M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 schizophrenia (the methyl-azoxymethanol acetate, MAM, model) that shows increased population activity of midbrain dopamine neurons. This study showed depolarization blockade is induced more rapidly in these animals than wild-type animals (23) , suggesting depolarization blockade may be more rapid in a hyperdopaminergic state. This contrasts with findings from an animal study using micro-dialysis, which showed no effect of chronic haloperidol treatment on striatal levels of extracellular dopamine and its metabolites (24) .
To date, only one study has examined effects of sub-chronic antipsychotic treatment in people with psychosis. This found decreased 18 F-DOPA uptake (k3) in striatum and thalamus in 9 antipsychoticfree people with schizophrenia, treated with haloperidol (25) . That study also found greater improvement in negative, but not positive symptoms, was associated with greater reduction in thalamic 18 F-DOPA uptake. This suggests reduction in dopamine synthesis capacity may be related to symptom change. However, the study by Gründer et al used haloperidol, a first-generation antipsychotic, at relatively high doses (mean dose 8.9mg/day); a dose that would be expected to result in D 2/3 occupancy >90% in first episode patients (17) , which might explain effects on the dopamine system. Modern clinical practice, however, involves treatment with second-generation antipsychotics, at lower relative doses, which would be expected to have lower D 2/3 occupancy (26).
It therefore remains unknown whether antipsychotic treatment with second generation antipsychotics at doses reflecting current practice decreases striatal dopamine synthesis capacity, and whether this has any relationship to symptom change.
We therefore sought to examine the effect of antipsychotic medication on striatal dopamine synthesis capacity in people experiencing their first episode of psychotic illness, and its relationship to symptom change.
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An exploratory analysis of associative striatum baseline Ki cer and symptomatic response was also conducted, based on a prior cross sectional study suggesting a relationship between this striatal subdivision and antipsychotic response (27) .
Methods and Materials
Ethical permission was obtained from the East of England-Cambridge East Ethics Committee, and Administration of Radioactive Substances Advisory Committee (ARSAC). All participants provided informed written consent to participate.
Participants

Inclusion criteria
Patients were recruited from first episode psychosis services in London. Inclusion criteria were: diagnosis of a psychotic disorder according to ICD 10 criteria (28), fulfilling criteria for a first episode of psychosis (29) , requiring treatment with antipsychotic medication; antipsychotic naïve or antipsychotic-free for at least 6 weeks (other clinical studies in similar populations requiring a minimum of 3 weeks antipsychotic-free (30, 31) .
For comparison a matched sample of healthy control subjects were included. Inclusion criteria included no psychiatric morbidity as assessed by the MINI-International Neuropsychiatric Interview (32) , and no contraindications to PET scanning, as per the patient sample." disorder and no contraindications to PET scanning, as per the patient sample.
Exclusion criteria for all subjects were: history of significant head trauma, dependence on illicit substances or alcohol, medical co-morbidity (other than minor illnesses, use of sodium valproate (due to effects on dopamine synthesis capacity (33) , and contra-indications to scanning (such as pregnancy).
Tobacco smoking was not an exclusion criterion.
Clinical measures
The following clinical measures were rated at baseline and at least 5 weeks after antipsychotic initiation: Positive and Negative Syndrome Scale (PANSS) (34) , Global Assessment of Functioning (GAF) (35) , and Clinical Global Impression-Improvement scale (CGI-I) (36) . Response status (dichotomized as "responder" versus "non-responder") was measured, in keeping with prior PET studies, based on a rating of "much improved" or "very much improved" on CGI (17) .
Baseline
People presenting with first episode psychosis received one baseline 18 F-DOPA scan prior to initiation of antipsychotic medication. They were classified as antipsychotic naïve, or medicationfree (free of oral antipsychotic medication for 6 weeks or longer).
Treatment
As this was a naturalistic study, antipsychotic treatment was decided by the treating clinician and patient. All doses were required to be within the therapeutic range for the drug defined in the Maudsley Prescribing Guidelines (36) . Use of other psychotropic medication (such as antidepressants and benzodiazepines) was permitted, though use of sodium valproate was not (as it may have effects on 18 F-DOPA uptake (33) . To assess concordance to antipsychotic medication, we used a multi-source approach, requiring evidence of adequate adherence on at least two of the following: antipsychotic plasma levels, pharmacy and electronic medical dispensing records, report from the patient and an independent source (family member/ carer or health care professional).
Adequate concordance was defined as taking a minimum of 80% of prescribed doses, in line with consensus recommendations (37) . To measure antipsychotic exposure we determined 
Follow-up
All participants received follow-up 18 F-DOPA scans and clinical measures (PANSS, GAF, CGI-I) after at least 5 weeks of antipsychotic treatment at an adequate dose as defined in the Maudsley Prescribing Guidelines and meeting concordance criteria described above.
Clinical follow-up was conducted six months after the baseline scan to confirm diagnosis, using the MINI.
F-DOPA PET imaging
All participants were asked not to eat or drink (except water), and refrain from alcohol for 12 hours prior to scan. Cigarette smokers were not permitted to smoke in the four hours preceding the scan.
The four hour cut The four hour cut The four hour cut
The four hour cut----off for last cigarette smoked in this study was based on evidence that nicotine's occupancy of off for last cigarette smoked in this study was based on evidence that nicotine's occupancy of off for last cigarette smoked in this study was based on evidence that nicotine's occupancy of off for last cigarette smoked in this study was based on evidence that nicotine's occupancy of the acetylcholine nicotinic receptor does not change appreciably between 2 the acetylcholine nicotinic receptor does not change appreciably between 2 the acetylcholine nicotinic receptor does not change appreciably between 2 the acetylcholine nicotinic receptor does not change appreciably between 2----5 hours after last administration of 5 hours after last administration of 5 hours after last administration of 5 hours after last administration of nicotine nicotine nicotine nicotine (40) (40) (40) (40). . . .
Imaging data were obtained on a Siemens Biograph 6 HiRez PET scanner (Siemens, Erlangen, Germany) in three-dimensional mode. One hour before scanning, participants received 400 mg entacapone, a peripheral catechol-o-methyl-transferase inhibitor, and 150mg carbidopa, a peripheral aromatic acid decarboxylase inhibitor, to prevent formation of radiolabeled metabolites that may cross the blood-brain barrier (41) . Participants were positioned in the scanner with the orbitomeatal line parallel to the transaxial plane of the tomograph. Head position was marked, monitored and movement minimized using a head strap. After acquiring a CT scan for attenuation correction, 18 F-DOPA was administered by bolus intravenous injection 30 seconds after start of PET imaging (see Table 2 for doses). PET data were acquired in 32 frames of increasing duration over the 95 min scan
(frame intervals: 8x15 seconds, 3x60 seconds, 5x120 seconds, 16x300 seconds).
The region-of-interest (ROI) analysis was conducted blind to medication status. Our primary endpoint was striatal influx constant (Ki cer , written as K i in some previous publications (42) for the whole striatum. For each participant, we calculated Ki cer for bilateral whole striatum, caudate, putamen, and thalamus, in light of prior work by Gründer et al (25) . Whole striatum was chosen instead of striatal functional subdivisions (such as Associative Striatum), given lack of prior investigation of striatal subdivisions and antipsychotic effects. Secondary analyses were also conducted with substantia nigra, given prior findings of a relationship between psychotic symptoms and dopamine synthesis capacity in substantia nigra (15) , and associative striatum and treatment response, based on prior literature (27) .
Correction for head movement during scan was performed by employing a mutual information algorithm (43) . SPM8 (44) was used to automatically normalize a tracer-specific 18 F-DOPA) template (45) together with the striatal brain atlas as defined by Martinez et al (46) and the Hammersmith brain atlas (47) . The Hammersmith brain atlas was used to identify extra-striatal regions and reference region (cerebellum). The region-of-interest atlas was transformed into the subject's PET space using the tracer specific template without using a co-registered MRI. This method has shown good reliability in a previous test re-test study (48) .
Ki cer was calculated using the Patlak-Gjedde graphical approach adapted for a reference tissue input function (49) . Further details of the image analysis approach are given in prior publications (16, 42) .
Though our reference region approach is robust to global differences in radiotracer delivery to the brain (50, 51), we examined the reference region (cerebellum) to ascertain change in standardized uptake value (SUV) in cerebellum at 95 minutes. To exclude potential effects of weight, we conducted correlation analysis of weight and Ki cer for participants at baseline. 2.05mm x 2mm = 8.41mm 3 ). This analysis was undertaken to investigate whether there was a change in striatal volume over time.
Statistical Analysis
Statistical analyses were performed using SPSS, version 23 (52) Change in dopamine synthesis capacity (DSC) was calculated as follows:
Results 20 patients completed the study and received two 18 F-DOPA scans. Fifteen were antipsychotic naive, and 5 were medication-free at time of scanning (previously receiving antipsychotic medication, and were medication-free for 6 weeks or longer). Of these patients, three did not meet the criteria for adequate treatment prior to the follow-up scan (one was treated with sub-therapeutic dose of antipsychotic medication because they declined to take higher doses, and two were non-concordant.)
We therefore excluded these three patients, leaving 17 patients to test hypothesis 1 (change in Ki cer after antipsychotic treatment).
All 20 patients were included to test hypothesis 2 (relationship between change in Ki cer and change in symptoms), as this was not dependent on antipsychotic treatment. Demographic and clinical details are given in Table 1 . Details of antipsychotic treatment that patients received after baseline scan are given in Supplementary Table 1 .
Median time between scans was 71 days (interquartile range 125 days).
No relationship was found between time between PET scans and change in Ki cer (rho=-0.03, p=0.92).
Of the 20 patients recruited in total, 12 people met criteria for schizophrenia and 8 for bipolar affective disorder at six month follow-up.
There was a statistically significant elevation in whole striatal Ki cer in patients compared to controls, (t(38)=2.32, p=0.03, two-tailed) (controls mean=12.41x10 -3 /min, SD=1.1x10 -3 /min).
Data on the baseline scans for 18 patients reported here have been published in (16) , and (53) . None of the follow-up scans have been previously reported.
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The 8 additional subjects did not receive follow-up F-DOPA PET scans.
[Insert Table 1 here.]
Antipsychotic treatment
Two patients started an antipsychotic but discontinued it due to side-effects and switched to another antipsychotic which they then received at an adequate dose and duration prior to follow-up scan.
Where this occurred, the discontinued medication is given first, followed by the drug they then received. Three patients took low dose aripiprazole to prevent weight gain and hyperprolactinemia in addition to the main antipsychotic. Where this occurred, the main antipsychotic is given first followed by aripiprazole to indicate its use as an adjunct. Regarding adjunctive medication, one patient was taking sertraline 150mg at initial scan, which was unchanged at follow-up.
There was a significant reduction in all symptoms following treatment ( Table 2) .
Baseline Ki cer and change in PANSS
There was a significant positive relationship between baseline associative striatum Ki cer and change in positive symptoms, r=0.52, p=0.03.
There was a significant positive relationship between baseline associative striatum Ki cer and change in total symptoms, r=0.49, p=0.045.
There was a trend for an association between whole striatum Ki cer and change in positive symptoms, r=0.48, p=0.05.
There was no association between whole striatum Ki cer and change in total symptoms, r=0.46, p=0.06.
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There was no association between whole striatum Ki cer and change in negative symptoms, spearman's rho=0.37, p=0.14.
[Insert Table 2 here.]
Change in dopamine synthesis capacity with antipsychotic medication
Median antipsychotic treatment received was 0.38 chlorpromazine dose years (interquartile range 0.36). There was no significant change in whole striatal dopamine synthesis capacity (Ki cer ) in people who received adequate treatment (baseline mean=13.07x10 -3 /min, SD=1.01x10 -3 /min; follow-up mean=12.85x10 -3 /min, SD=1.09x10 -3 /min, t(16)=0.74, p=0.47) ( Figure 1 ).
[Insert Figure 1 here.]
Data points for all subjects are given as a scatterplot in Supplementary Figure 1 , categorized as responders, non-responders (using CGI-I), and subjects taking sub-therapeutic medication and those non-concordant with antipsychotic medication.
As aripiprazole is a partial agonist, in contrast to a full antagonist, and thus may have different effects, we repeated the analyses after excluding the two subjects who received aripiprazole monotherapy, and repeated the analysis after excluding all subjects taking aripiprazole, including those taking it as an adjunct to a dopamine antagonist. There was no significant effect of antipsychotic treatment on Ki cer after restricting the analyses to subjects taking full antagonists in either analysis (p=0.4 and p=0.91 respectively).
There was no significant effect of treatment on Ki cer for the other regions analyzed (striatal functional subdivisions, caudate, putamen, thalamus or substantia nigra; see Table 3 ).
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[Insert Table 3 here.]
There was no change in standardized uptake value (SUV) in the reference region (cerebellum) with treatment (baseline mean=1.3x10 -3 /min, SD=0.35x10 -3 /min, and follow-up mean=1.45x10 -3 /min, SD=0.58x10 -3 /min, t (16) =-1.27, p=0.15). There was no change in striatal volume before and after antipsychotic treatment (baseline mean=2006.53mm, SD=180.54mm) and follow-up (mean=2047.94mm, SD=216.43mm), t(16)=-1.39, p=0.18). There was no effect of weight on Ki cer (r=0.08, p=0.73).
Relationship between change in dopamine synthesis capacity and symptom change
There was no significant correlation between percentage decrease in whole striatal Ki cer and percentage improvement in PANSS positive (n=20, rho=0.35, p=0.13), total (rho=0.25, p=0.29), or negative symptoms (rho=0.1, p=0.68, see Figure 2 ).
[Insert Figure 2 here] There was no relationship between change in thalamic Ki cer and change in PANSS negative symptom severity score in people taking antipsychotic treatment (n=17, rho=-0.26, p=0.31).
Discussion
Our main findings are that there is no significant change in striatal dopamine synthesis capacity with antipsychotic treatment, and no significant association between change in dopamine synthesis capacity and change in psychotic symptoms. To the best of our knowledge this is the first study to measure change in dopamine synthesis capacity after treatment with second-generation antipsychotics.
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Effects of antipsychotic medication on presynaptic dopamine function
Our finding of no change in presynaptic striatal dopamine function with prolonged antipsychotic treatment is consistent with acute studies in healthy volunteers, which found no significant overall change in dopamine synthesis capacity after treatment with a number of different antipsychotic drugs (54) (55) (56) . However, our findings contrast to the only other study examining effects in a markedly smaller sample of people with schizophrenia (25) , which found decrease in dopamine synthesis capacity in caudate and putamen after a mean of 5 weeks' haloperidol treatment. A possible explanation could be relatively high dose of haloperidol (almost double the chlorpromazineequivalent dose in our study). Thus, taken together with our findings, this suggests that whilst higher doses of antipsychotics may have effects, antipsychotic treatment at doses in the range typically used in current practice is not associated with significant changes in dopamine synthesis capacity.
Our study differed from the Grunder study in terms of experimental design and methodology for quantification of F-DOPA kinetics, and is therefore not directly comparable. From a methodological perspective the two parameters of interest (k3 in the Grunder study and Ki cer in our study) are different. Ki cer is related to k3 and Ki cer in our study (57) but also dependent on perfusion and tissueto-blood tracer diffusion. One major methodological difference is the length of scan (120 minutes in the Grunder study compared to 95 minutes in our study). There is evidence from monkey and human studies that metabolism of radiolabelled dopamine becomes appreciable by 120 minutes (58, 59) . As dopamine metabolism is not accounted for in the analysis used by Grunder et al, this could introduce noise into the measurement of k3.
It is also worth noting that, in Grunder et al, the authors found, after haloperidol, an increase in absolute terms of radiolabelled dopa volume of distribution and reduction in radiolabelled dopa from striatal tissue back across the blood brain barrier. We did not measure these parameters, although,
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Micro-dialysis findings show antipsychotic treatment acutely induces a transient increase in striatal extracellular dopamine levels, which fall back to basal levels with chronic treatment (24) . Our results are consistent with these findings, and extend them to show that, in addition to having no lasting effect on extracellular dopamine levels, chronic treatment does not alter dopamine synthesis capacity. It should be recognized that we did not measure dopamine neuron firing and so our findings cannot exclude an effect on midbrain dopamine neuron firing, as seen in the electrophysiology studies of chronic antipsychotic treatment (20) . Determining this will require preclinical studies to test the relationship between dopamine neuron firing, striatal dopamine levels and dopamine synthesis capacity.
We did not find a change in striatal volume with antipsychotics in our study. A systematic review of the effects of second generation antipsychotics, such as used in our study, found inconsistent effects on striatal volume, with some studies reporting increases, others finding decreases, and others finding no effects, as is the case in our study (60) .
Limitations
Our study was powered to detect a statistically significant difference and relationship between change in symptoms and change in dopamine synthesis capacity of the size reported by Grunder and colleagues. Whilst a type II error remains possible, the data suggest any effect is unlikely to be clinically significant. It should be acknowledged that the follow-up at six months showed the patient group included patients who subsequently met diagnostic criteria for bipolar affective disorder as well as schizophrenia. It is often not possible to disentangle diagnosis at baseline though we should emphasize that criteria for study entry were presence of psychosis, according to criteria used before to define psychosis in first episode illness (61) , and requiring antipsychotic treatment (62) .
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It should be noted that four hours post It should be noted that four hours post It should be noted that four hours post It should be noted that four hours post----cigarette could correspond to the period of subjective nicotine cigarette could correspond to the period of subjective nicotine cigarette could correspond to the period of subjective nicotine cigarette could correspond to the period of subjective nicotine withdrawal, although nicotine's occupancy of nicotinic receptors in the brain remains withdrawal, although nicotine's occupancy of nicotinic receptors in the brain remains withdrawal, although nicotine's occupancy of nicotinic receptors in the brain remains withdrawal, although nicotine's occupancy of nicotinic receptors in the brain remains high high high high (40) (40) (40) (40). . . .
It is conceivable that antipsychotics could have had an effect on blood flow (63) , and effects on tracer delivery to the reference region (cerebellum). Our finding of no difference in SUV in cerebellum, suggests this is not a significant issue, though further studies are required to exclude this, and investigate local blood flow changes. Moreover, it is unlikely to account for our findings, as this would require opposite blood flow effects in the cerebellum to the striatum to account for no overall change. Ideally, tests of the biological effect of antipsychotic drugs would involve randomizing patients to placebo treatment as well as excluding non-specific effects of treatment. This would have ethical implications and is therefore unlikely to be feasible.
Implications for clinical care
Our main finding, that antipsychotics do not alter dopamine synthesis capacity in people presenting with first episode psychosis, extends cross-sectional evidence that dopamine synthesis capacity remains elevated, even in patients on long-term antipsychotic treatment (12, 64) , to indicate that antipsychotics do not normalize the major (pre-synaptic) dopaminergic abnormality seen in the disorder. This provides a potential neurobiological explanation for why psychosis recurs after antipsychotic treatment is stopped (65) , and, potentially for continued treatment, as it suggests that stopping dopamine receptor blockade would lead to dopamine dysfunction being unmasked. Supplementary Table S1 . 
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